U.S. markets closed
  • S&P 500

    4,288.05
    -11.65 (-0.27%)
     
  • Dow 30

    33,507.50
    -158.84 (-0.47%)
     
  • Nasdaq

    13,219.32
    +18.05 (+0.14%)
     
  • Russell 2000

    1,785.10
    -9.21 (-0.51%)
     
  • Crude Oil

    90.77
    -0.94 (-1.02%)
     
  • Gold

    1,864.60
    -14.00 (-0.75%)
     
  • Silver

    22.39
    -0.35 (-1.54%)
     
  • EUR/USD

    1.0575
    +0.0008 (+0.07%)
     
  • 10-Yr Bond

    4.5730
    -0.0240 (-0.52%)
     
  • GBP/USD

    1.2201
    -0.0005 (-0.04%)
     
  • USD/JPY

    149.3300
    +0.0560 (+0.04%)
     
  • Bitcoin USD

    27,031.18
    +99.69 (+0.37%)
     
  • CMC Crypto 200

    579.66
    +0.90 (+0.15%)
     
  • FTSE 100

    7,608.08
    +6.23 (+0.08%)
     
  • Nikkei 225

    31,857.62
    -14.90 (-0.05%)
     

CORRECTING and REPLACING Acadia Healthcare Reports Third Quarter 2022 Results

Same Facility Revenue Increases 10.2%

FRANKLIN, Tenn., October 31, 2022--(BUSINESS WIRE)--There was an inadvertent error on the supplementary table titled "Reconciliation of Net Income Attributable to Acadia Healthcare Company, Inc. to Adjusted Income Attributable to Acadia Healthcare Company, Inc." on page 11 of the previous release, within the line item titled "Income tax effect of adjustments to income" and the resulting calculations of Adjusted income and Adjusted income per diluted share in the table. The table has been corrected and there were no other changes to the release.

The updated release reads:

ACADIA HEALTHCARE REPORTS THIRD QUARTER 2022 RESULTS

Same Facility Revenue Increases 10.2%

Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced financial results for the third quarter ended September 30, 2022.

Third Quarter Highlights

  • Revenue totaled $666.7 million, an increase of 13.5% over the third quarter of 2021

  • Same facility revenue increased 10.2% compared to the third quarter of 2021, including an increase in revenue per patient day of 6.9% and an increase in patient days of 3.1%

  • Net income attributable to Acadia totaled $71.1 million, or $0.78 per diluted share, and adjusted income from continuing operations attributable to Acadia stockholders totaled $73.3 million, or $0.86 per diluted share, which included $0.06 of income from the Provider Relief Fund ("PRF") established under the Coronavirus Aid, Relief, and Economic Security ("CARES") Act

  • Adjusted EBITDA totaled $162.8 million, which included $7.7 million of income from the PRF established under the CARES Act

  • Opened a de novo children’s hospital in Chicago, a joint venture facility in Knoxville, and two new Comprehensive Treatment Centers ("CTCs")

Third Quarter Results

The Company reported revenue of $666.7 million for the third quarter of 2022, compared with $587.6 million for the third quarter of 2021. Adjusted EBITDA was $162.8 million for the third quarter of 2022, compared with $141.9 million for the same period last year. Excluding income from the PRF, Adjusted EBITDA was $155.1 million for the third quarter of 2022.

The Company recorded income from the PRF of $7.7 million in the third quarter of 2022. The Company will continue to review the remaining $14.2 million of American Rescue Plan ("ARP") Rural Payments held on its balance sheet as of September 30, 2022, for the potential recognition of additional income. Financial guidance for 2022 does not include the recognition of additional income in the fourth quarter of 2022 beyond the $16.2 million recorded in the nine months ended September 30, 2022.

Net income attributable to Acadia stockholders for the third quarter of 2022 was $71.1 million, or $0.78 per diluted share. Adjusted income from continuing operations attributable to Acadia stockholders was $0.86 per diluted share for the third quarter of 2022. Excluding income from the PRF, adjusted income from continuing operations was $0.80 per diluted share for the third quarter of 2022. Adjustments to income include transaction-related expenses and the income tax effect of adjustments to income. A reconciliation of all non-GAAP financial results in this press release begins on page 10.

For the third quarter of 2022, Acadia’s same facility revenue increased 10.2% compared with the third quarter of 2021, including an increase in revenue per patient day of 6.9% and an increase in patient days of 3.1%.

Chris Hunter, Chief Executive Officer of Acadia Healthcare Company, remarked, "We continued to see robust demand for our behavioral healthcare services during the third quarter. We executed our strategy with favorable results across our key performance metrics including continued navigation through a tight labor market. We are fortunate to have an experienced and dedicated team of employees and clinicians across our operations who have worked tirelessly to meet the needs of those seeking treatment for mental health and substance use issues.

Strategic Investments for Long-Term Growth

"We have progressed on our key growth initiatives across all our service lines this year. We continue to make critical investments in our business to support sustained long-term growth through four distinct pathways. Facility expansions are our first and most efficient growth pathway as we can expand services in established markets with our existing infrastructure and experienced staff. We added 132 beds to our existing facilities during the third quarter, bringing our total number of bed additions to 210 for the first nine months of the year. We are on track to meet our goal of adding approximately 300 beds in 2022.

"For our second growth pathway, we continue to develop wholly owned de novo facilities that meet the critical demand for behavioral healthcare services in underserved markets. There are significant opportunities across the country to address this unmet need at the local community level. We opened a 60-bed children’s hospital in early July, as the first stage of our Montrose Behavioral Health Hospital operations in Chicago. In addition to the children’s hospital, we expect to begin operations at our 101-bed adult hospital and the outpatient facility in 2023 following the renovations of these facilities.

"We continue to identify opportunities to expand our network of CTCs to address the critical need for addiction treatment, specifically for patients dealing with opioid use disorder. During the third quarter, we opened new CTCs in Indiana and Florida. This brings our total to four CTCs opened this year, supporting our objective to open at least six new CTCs in 2022. As the opioid crisis has continued to escalate across the country, our CTC facilities and programs are playing a vital role in addressing this national epidemic.

"A third important pathway for growth for Acadia is forming strategic partnerships with leading health systems across the country. We are proud to work with a growing number of premier health systems to expand behavioral healthcare treatment options in their respective communities. By working together, we can leverage our behavioral health expertise and implement best practices to deliver high quality care and positive clinical outcomes for more patients. During the third quarter, we opened a new facility with our joint venture partner, Covenant Health, in Knoxville, Tennessee. We also broke ground on a new state-of-the-art behavioral health treatment and teaching hospital with our joint venture partner, Henry Ford Health, in the Detroit, Michigan metropolitan area. We expect to commence operations at Maple Heights Behavioral Health, our joint venture with Lutheran Health Network of Indiana during the fourth quarter. An important aspect of many of our joint venture partnerships is the academic focus and training of future clinicians. During the quarter, our Belmont Behavioral Health Hospital in Philadelphia entered into a formal affiliation agreement with Thomas Jefferson University’s Sidney Kimmel Medical College and Jefferson Health in Philadelphia, Pennsylvania, to further teaching and clinical care opportunities for students in behavioral healthcare.

"For our fourth pathway, we focus on identifying strategic acquisition opportunities that allow us to leverage our scale and expertise, make necessary investments for expansion and add service offerings to further enhance the continuum of care. We are fortunate to have a strong balance sheet that supports our ability to pursue acquisitions along with opportunities through our other important growth pathways," added Hunter.

Cash and Liquidity

Maintaining a strong financial position is a top priority for Acadia, providing the flexibility to pursue its growth initiatives and make strategic investments in its business. As of September 30, 2022, the Company had $93.4 million in cash and cash equivalents. The Company had $515 million available under its $600 million revolving credit facility and its net leverage ratio was approximately 2.1x as of September 30, 2022.

During the third quarter, the Company substantially completed its repayment of amounts received pursuant to the Medicare Accelerated and Advanced Payment Program under the CARES Act. Of the $45.2 million of advanced payments received in 2020, the Company repaid a total of $25.1 million in 2021 and made additional payments of $18.9 million through the first nine months of 2022. The Company will pay off the remaining balance of $1.2 million in the fourth quarter of 2022. In the third quarter of 2022, the Company repaid the remaining half of the approximately $39.3 million of 2020 payroll tax deferrals, which eliminated this liability.

Financial Guidance

Acadia today narrowed its previously announced financial guidance for 2022, as follows:

2022 Guidance Range

Revenue

$2.58 to $2.60 billion

Adjusted EBITDA, including income from the PRF

$611 to $621 million

Adjusted EBITDA, excluding income from the PRF

$595 to $605 million

Adjusted earnings per diluted share, including

income from the PRF

$3.13 to $3.23

Adjusted earnings per diluted share, excluding

income from the PRF

$3.00 to $3.10

Interest expense

Approximately $70 million

Tax rate

25% to 26%

Depreciation and amortization expense

Approximately $120 million

Stock compensation expense

Approximately $30 million

Operating cash flows

$360 to $400 million

Expansion capital expenditures

$210 to $230 million

Maintenance capital expenditures

Approximately $60 million

The Company’s guidance does not include the impact of any future acquisitions, divestitures or transaction-related expenses.

Looking Ahead

Hunter added, "We look forward to hosting Acadia’s first Investor Day on Wednesday, December 7, 2022, in New York City. Our management team will provide an in-depth look at our diverse service lines and our strategic initiatives to advance our leadership position in the behavioral healthcare industry.

"We are excited about the opportunities ahead for Acadia, as we remain focused on our primary objective to extend our market reach through our four defined growth pathways. Demand for our services continues to grow, and we believe we are well positioned to maintain our strong growth trajectory and meet our development targets for the year. Without question, the critical need for behavioral health treatment has become a primary focus for health officials, medical professionals, and lawmakers across the country, with depression and anxiety issues further amplified by the strains of the COVID-19 pandemic. Recent data from the Centers for Disease Control and Prevention showed the U.S. suicide rate rose four percent in 2021 after two consecutive years of declines, highlighting the critical need for early assessment and intervention. As a leading provider of behavioral healthcare services, we play a vital role in addressing this need, and we believe we have the right strategy in place to make a positive difference. We are proud of the important work we are doing as we continue to pursue a strategic direction that delivers greater value for our patients, the communities we serve, and our stockholders."

Conference Call

Acadia will hold a conference call to discuss its third quarter financial results at 9:00 a.m. Eastern Time on November 1, 2022. A live webcast of the conference call will be available at www.acadiahealthcare.com in the "Investors" section of the website. The webcast of the conference call will be available for 30 days.

About Acadia

Acadia is a leading provider of behavioral healthcare services across the United States. As of September 30, 2022, Acadia operated a network of 242 behavioral healthcare facilities with approximately 10,800 beds in 39 states and Puerto Rico. With more than 22,500 employees serving approximately 70,000 patients daily, Acadia is the largest stand-alone behavioral healthcare company in the U.S. Acadia provides behavioral healthcare services to its patients in a variety of settings, including inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers and outpatient clinics.

Forward-Looking Information

This press release contains forward-looking statements. Generally, words such as "may," "will," "should," "could," "anticipate," "expect," "intend," "estimate," "plan," "continue," and "believe" or the negative of or other variation on these and other similar expressions identify forward-looking statements. These forward-looking statements are made only as of the date of this press release. We do not undertake to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise. Forward-looking statements are based on current expectations and involve risks and uncertainties and our future results could differ significantly from those expressed or implied by our forward-looking statements. Factors that may cause actual results to differ materially include, without limitation, (i) the impact of the COVID-19 pandemic, including, without limitation, disruption to the U.S. economy and financial markets; reduced admissions and patient volumes; and increased costs relating to labor, supply chain and other expenditures; (ii) the impact of vaccine and other pandemic-related mandates imposed by local, state and federal authorities; (iii) potential difficulties in successfully integrating the operations of acquired facilities or realizing the expected benefits and synergies of our facility expansions, acquisitions, joint ventures and de novo transactions; (iv) Acadia’s ability to add beds, expand services, enhance marketing programs and improve efficiencies at its facilities; (v) potential reductions in payments received by Acadia from government and third-party payors; (vi) the occurrence of patient incidents, governmental investigations, litigation and adverse regulatory actions, which could adversely affect the price of our common stock and result in substantial payments and incremental regulatory burdens; (vii) the risk that Acadia may not generate sufficient cash from operations to service its debt and meet its working capital and capital expenditure requirements; (viii) potential disruptions to our information technology systems or a cybersecurity incident; and (ix) potential operating difficulties, labor costs, client preferences, changes in competition and general economic or industry conditions that may prevent Acadia from realizing the expected benefits of its business strategies. These factors and others are more fully described in Acadia’s periodic reports and other filings with the SEC.

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended September 30,

Nine Months Ended September 30,

2022

2021

2022

2021

(In thousands, except per share amounts)

Revenue

$

666,732

$

587,559

$

1,935,104

$

1,720,914

Salaries, wages and benefits (including equity-based compensation expense of $7,240, $8,923, $21,745 and $24,988, respectively)

352,582

309,118

1,027,732

922,684

Professional fees

40,367

35,602

117,718

101,915

Supplies

25,570

23,743

74,291

67,698

Rents and leases

11,339

9,658

33,780

28,690

Other operating expenses

88,993

76,502

255,355

222,263

Income from provider relief fund

(7,656

)

(16,206

)

Depreciation and amortization

29,573

27,805

87,627

78,349

Interest expense, net

18,003

15,706

50,355

61,420

Debt extinguishment costs

24,650

Loss on impairment

1,079

24,293

Transaction-related expenses

10,859

3,035

18,381

9,320

Total expenses

569,630

502,248

1,649,033

1,541,282

Income from continuing operations before income taxes

97,102

85,311

286,071

179,632

Provision for income taxes

24,056

17,411

69,183

42,948

Income from continuing operations

73,046

67,900

216,888

136,684

Loss from discontinued operations, net of taxes

(12,641

)

Net income

73,046

67,900

216,888

124,043

Net income attributable to noncontrolling interests

(1,947

)

(1,774

)

(4,873

)

(3,686

)

Net income attributable to Acadia Healthcare Company, Inc.

$

71,099

$

66,126

$

212,015

$

120,357

Basic earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:

Income from continuing operations attributable to Acadia Healthcare Company, Inc.

$

0.79

$

0.74

$

2.37

$

1.50

Loss from discontinued operations

$

(0.14

)

Net income attributable to Acadia Healthcare Company, Inc.

$

0.79

$

0.74

$

2.37

$

1.36

Diluted earnings per share attributable to Acadia Healthcare Company, Inc. stockholders:

Income from continuing operations attributable to Acadia Healthcare Company, Inc.

$

0.78

$

0.73

$

2.31

$

1.47

Loss from discontinued operations

$

(0.14

)

Net income attributable to Acadia Healthcare Company, Inc.

$

0.78

$

0.73

$

2.31

$

1.33

Weighted-average shares outstanding:

Basic

89,833

88,962

89,607

88,684

Diluted

91,723

90,889

91,668

90,604

Acadia Healthcare Company, Inc.

Condensed Consolidated Balance Sheets

(Unaudited)

September 30,

December 31,

2022

2021

(In thousands)

ASSETS

Current assets:

Cash and cash equivalents

$

93,419

$

133,813

Accounts receivable, net

315,999

281,332

Other current assets

112,238

79,886

Total current assets

521,656

495,031

Property and equipment, net

1,908,993

1,771,159

Goodwill

2,207,912

2,199,937

Intangible assets, net

75,920

70,145

Deferred tax assets

2,983

3,080

Operating lease right-of-use assets

135,627

133,761

Other assets

90,014

94,965

Total assets

$

4,943,105

$

4,768,078

LIABILITIES AND EQUITY

Current liabilities:

Current portion of long-term debt

$

21,250

$

18,594

Accounts payable

116,045

98,575

Accrued salaries and benefits

109,654

137,845

Current portion of operating lease liabilities

25,770

23,348

Other accrued liabilities

128,294

126,499

Total current liabilities

401,013

404,861

Long-term debt

1,379,306

1,478,626

Deferred tax liabilities

94,446

74,368

Operating lease liabilities

117,473

116,841

Other liabilities

118,923

110,505

Total liabilities

2,111,161

2,185,201

Redeemable noncontrolling interests

88,236

65,388

Equity:

Common stock

899

890

Additional paid-in capital

2,650,545

2,636,350

Retained earnings (accumulated deficit)

92,264

(119,751

)

Total equity

2,743,708

2,517,489

Total liabilities and equity

$

4,943,105

$

4,768,078

Acadia Healthcare Company, Inc.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Nine Months Ended September 30,

2022

2021

(In thousands)

Operating activities:

Net income

$

216,888

$

124,043

Adjustments to reconcile net income to net cash provided by continuing operating activities:

Depreciation and amortization

87,627

78,349

Amortization of debt issuance costs

2,440

3,265

Equity-based compensation expense

21,745

24,988

Deferred income taxes

20,176

8,995

Loss from discontinued operations, net of taxes

12,641

Debt extinguishment costs

24,650

Loss on impairment

24,293

Other

2,422

881

Change in operating assets and liabilities, net of effect of acquisitions:

Accounts receivable, net

(35,538

)

(8,610

)

Other current assets

(28,692

)

(2,758

)

Other assets

3,373

(15,846

)

Accounts payable and other accrued liabilities

7,729

6,358

Accrued salaries and benefits

(8,831

)

18,820

Other liabilities

10,303

(11,633

)

Government relief funds

(32,617

)

(12,058

)

Net cash provided by continuing operating activities

267,025

276,378

Net cash provided by discontinued operating activities

253

Net cash provided by operating activities

267,025

276,631

Investing activities:

Cash paid for capital expenditures

(208,792

)

(156,624

)

Proceeds from U.K. Sale

1,511,020

Settlement of foreign currency derivatives

(84,795

)

Proceeds from sale of property and equipment

1,784

1,792

Cash paid for purchase of finance lease

(31,401

)

Other

(6,802

)

...